Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant.
暂无分享,去创建一个
F. Vasseur | L. Michaux | F. Bauters | N. Dastugue | T. Facon | M. Zandecki | J. Laï | A. Daudignon
[1] International System for Human Cytogenetic Nomenclature , 2020, Definitions.
[2] L. Zech,et al. 2 translocations, t(11;14) and t(1;6), in a patient with plasma cell leukaemia and 2 populations of plasma cells. , 2009, Scandinavian journal of haematology.
[3] T. Facon,et al. MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL , 1996, British journal of haematology.
[4] D. Gerhard,et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. , 1996, Blood.
[5] M. Taniwaki,et al. Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. , 1996, Leukemia & lymphoma.
[6] C. Mecucci,et al. Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma. , 1995, Cancer genetics and cytogenetics.
[7] B. Quesnel,et al. The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. , 1995, Leukemia & lymphoma.
[8] M. Nair,et al. Nonrandom karyotype abnormalities in 36 multiple myeloma patients. , 1995, Cancer genetics and cytogenetics.
[9] B. Barlogie,et al. Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.
[10] C. Louvet,et al. Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques , 1995, British journal of haematology.
[11] J. Mary,et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. , 1995, Blood.
[12] E. Solary,et al. Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt's-type translocations. , 1995, Leukemia.
[13] M. Taniwaki,et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. , 1994, Blood.
[14] B. Barlogie,et al. Deletion of the retinoblastoma gene in multiple myeloma. , 1994, Leukemia.
[15] E. Wattel,et al. Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients , 1993, British journal of haematology.
[16] S. Swerdlow,et al. Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma. , 1993, Leukemia.
[17] R. Berger,et al. Chromosome studies in plasma cell leukemia and multiple myeloma in transformation , 1992, Genes, chromosomes & cancer.
[18] N. Harris,et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[19] J. Delabie,et al. Translocation (11;14): A cytogenetic anomaly associated with B‐cell lymphomas of non‐follicle centre cell lineage , 1991, The Journal of pathology.
[20] L. Cro,et al. Ras oncogene mutation in multiple myeloma , 1989, The Journal of experimental medicine.
[21] I. Lisse,et al. Occurrence and type of chromosomal abnormalities in consecutive malignant monoclonal gammopathies: correlation with survival. , 1988, Cancer genetics and cytogenetics.
[22] B. Barlogie,et al. Plasma Cell Karyotype in Multiple Myeloma , 1988 .
[23] P. Bevan,et al. Analysis of G banded karyotypes in myeloma cells. , 1986, Journal of clinical pathology.
[24] R. Kyle,et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. , 1985, Blood.
[25] Jerry P. Lewis,et al. Non‐random chromosomal aberrations associated with multiple myeloma , 1984, Hematological oncology.
[26] S. Raptis,et al. Cytogenetic study in multiple myeloma. , 1984, Cancer genetics and cytogenetics.
[27] K. Takatsuki,et al. Cytogenetic studies and clinical aspects of patients with plasma cell leukemia and leukemic macroglobulinemia. , 1983, Cancer research.
[28] B. Durie. Staging and kinetics of multiple myeloma. , 1982, Seminars in oncology.
[29] J. Rowley,et al. Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders , 1979, Cancer.
[30] E. Schuuring,et al. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene. , 1997, Blood.
[31] K. Uchimaru,et al. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32). , 1995, Acta haematologica.
[32] D. Hossfeld,et al. Karyotype in multiple myeloma and plasma cell leukaemia. , 1993, European journal of cancer.
[33] C. Mecucci,et al. Translocation t(11;14) and trisomy 11q13----qter in multiple myeloma. , 1984, Annales de genetique.